Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Rises By 32.1%

Century Therapeutics, Inc. (NASDAQ:IPSC) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 325,386 shares, a growth of 32.1% from the December 15th total of 246,333 shares. Based on an average trading volume of 1,916,134 shares, the short-interest ratio is currently 0.2 days. Approximately 0.4% of the shares of the stock are sold short. Approximately 0.4% of the shares of the stock are sold short. Based on an average trading volume of 1,916,134 shares, the short-interest ratio is currently 0.2 days.

Insider Buying and Selling at Century Therapeutics

In related news, insider Chad Cowan purchased 58,060 shares of the stock in a transaction dated Monday, December 22nd. The shares were acquired at an average cost of $0.85 per share, with a total value of $49,351.00. Following the purchase, the insider directly owned 1,045,087 shares in the company, valued at $888,323.95. This trade represents a 5.88% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Brent Pfeiffenberger purchased 52,000 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was bought at an average price of $0.58 per share, with a total value of $30,160.00. Following the acquisition, the chief executive officer directly owned 3,322,990 shares in the company, valued at approximately $1,927,334.20. This represents a 1.59% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 145,060 shares of company stock valued at $97,011 and sold 65,987 shares valued at $29,798. Corporate insiders own 4.37% of the company’s stock.

Hedge Funds Weigh In On Century Therapeutics

A number of institutional investors have recently modified their holdings of the company. Two Sigma Investments LP boosted its position in Century Therapeutics by 59.2% during the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock worth $454,000 after acquiring an additional 338,902 shares during the last quarter. GSA Capital Partners LLP raised its holdings in Century Therapeutics by 29.3% in the 3rd quarter. GSA Capital Partners LLP now owns 603,479 shares of the company’s stock valued at $301,000 after acquiring an additional 136,873 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Century Therapeutics during the 2nd quarter worth $248,000. Citadel Advisors LLC boosted its holdings in shares of Century Therapeutics by 64.1% during the third quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock worth $180,000 after purchasing an additional 140,891 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of Century Therapeutics by 101.2% in the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after purchasing an additional 142,953 shares during the period. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Stock Performance

Century Therapeutics stock opened at $2.17 on Friday. Century Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.32. The company has a market capitalization of $189.66 million, a price-to-earnings ratio of -6.78 and a beta of 1.72. The stock has a fifty day moving average of $0.89 and a two-hundred day moving average of $0.67.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. On average, analysts forecast that Century Therapeutics will post -1.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on IPSC shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Leerink Partnrs downgraded Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Zacks Research upgraded Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 20th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down previously from $7.00) on shares of Century Therapeutics in a research note on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $3.40.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.